Step into the future of regenerative biologics with the patented PURE® SupraPhysiologic Concentrating System featuring AspiraDome™ technology. AspiraDome™ is a guided buffycoat collection innovation that optimizes platelet and progenitor cell collection. This new innovation brings SupraPhysiologic processing to perfection allowing it to be the most advanced autologous concentrating system ever developed for point of care applications. It’s purpose-built to eliminate variability and maximize performance. This next-generation system redefines what’s possible in point-of-care biologic preparation.

PurePRP® SupraPhysiologic (PurePRP® SP) is a proprietary form of autologous platelet rich plasma developed by EmCyte Corporation.  It contains a complex composition of cellular components derived from your blood biologic that can be used to treat and repair a host of injuries and conditions.  It is the cornerstone of the consortium of regenerative therapies used in modern medicine and rapidly becoming a standard of care. It’s chosen over surgery for many conditions, ranging from degenerative joint disease, to tendon and ligament injuries because its regenerative power is shown to play an adjunctive role in clinical outcomes. It is unique in that it is the only point of care system that selectively removes wound inhibiting factors while concentrating regenerative cellular components. This powerful capability distinguishes the PURE SupraPhysiologic brand, making it the most dominant PRP in the overall market, according to Grand View Research project.  Its wheelhouse is PURE POWER, PURE SIMPLICITY, and PURE HEALING. 

PurePRP® has been used by physicians to treat various conditions involving:

PurePRP® has been used as effective add-on to surgery in various surgical procedures including: